The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
Abstract
Purpose: To update the 2000 ASCO guidelines on the role of bisphosphonates in women with breast cancer and address the subject of bone health in these women. Results: For patients with plain radiographic evidence of bone destruction, intravenous pamidronate 90 mg delivered over 2 hours or zoledronic acid 4 mg over 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence supporting the efficacy of one bisphosphonate over the other. Starting bisphosphonates in women who demonstrate bone destruction through imaging but who have normal plain radiographs is considered reasonable treatment. Starting bisphosphonates in women with only an abnormal bone scan but without evidence of bone destruction is not recommended. The presence or absence of bone pain should not be a factor in initiating bisphosphonates. In patients with a serum creatinine less than 3.0 mg/dL (265 μmol/L), no change in dosage, infusion time, or interval is required. Infusion times less than 2 hours with pamidronate or less than 15 minutes with zoledronic acid should be avoided. Creatinine should be monitored before each dose of either agent in accordance with US Food and Drug Administration (FDA) labeling. Oncology professionals, especially medical oncologists, need to take an expanded role in the routine and regular assessment of the osteoporosis risk in women with breast cancer. The panel recommends an algorithm for patient management to maintain bone health. Conclusion: Bisphosphonates provide a supportive, albeit expensive and non–life-prolonging, benefit to many patients with bone metastases. Current research is focusing on bisphosphonates as adjuvant therapy. Although new data addressing when to stop therapy, alternative doses or schedules for administration, and how to best coordinate bisphosphonates with other palliative therapies are needed, they are not currently being investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Diagnosis of osteoporosis and assessment of fracture risk
Kanis, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08761-5 · Cited by 2,260
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Self-citationHortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Self-citationPathogenesis of bone fragility in women and men
Seeman, E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08706-8 · Cited by 909
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,488
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650
Self-citationStopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Self-citationRuggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.009 · Cited by 1,328
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Zheng, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh141 · Cited by 1,201
Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L. A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8670 · Cited by 1,149
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,118
Self-citationWiner, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Self-citationHypercalcemia Associated with Cancer
Stewart, A. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042806 · Cited by 973
(2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.11.003 · Cited by 837
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Saad, F., Lipton, A., Cook, R., Chen, Y., Smith, M., & Coleman, R. (2007) · Cancer · doi:10.1002/cncr.22991 · Cited by 667
Self-citationKohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., & Takashima, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.116 · Cited by 546
Coleman, R. E., Major, P., Lipton, A., Brown, J. E., Lee, K.-A., Smith, M., Saad, F., Zheng, M., Hei, Y. J., Seaman, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.091 · Cited by 533
Self-citationFizazi, K., Lipton, A., Mariette, X., Body, J.-J., Rahim, Y., Gralow, J. R., Gao, G., Wu, L., Sohn, W., & Jun, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2146 · Cited by 533
Self-citationRuggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Australian Endodontic Journal · doi:10.1111/j.1747-4477.2009.00213.x · Cited by 505
Body, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1933 · Cited by 490
Self-citationMigliorati, C. A., Schubert, M. M., Peterson, D. E., & Seneda, L. M. (2005) · Cancer · doi:10.1002/cncr.21130 · Cited by 489
Ellis, G. K., Bone, H. G., Chlebowski, R., Paul, D., Spadafora, S., Smith, J., Fan, M., & Jun, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3832 · Cited by 483
Self-citationManaging the care of patients with bisphosphonate-associated osteonecrosis
MIGLIORATI, C. A., CASIGLIA, J., EPSTEIN, J., JACOBSEN, P. L., SIEGEL, M. A., & WOO, S.-B. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0108 · Cited by 468
Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0012 · Cited by 450
Coleman, R. E., Banks, L. M., Girgis, S. I., Kilburn, L. S., Vrdoljak, E., Fox, J., Cawthorn, S. J., Patel, A., Snowdon, C. F., Hall, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70003-7 · Cited by 426
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Self-citationFerris, F. D., Bruera, E., Cherny, N., Cummings, C., Currow, D., Dudgeon, D., JanJan, N., Strasser, F., von Gunten, C. F., & Von Roenn, J. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1558 · Cited by 396
Self-citationBodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Bisphosphonates: Clinical Experience
Coleman, R. E. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-14 · Cited by 384
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment
Migliorati, C. A., Siegel, M. A., & Elting, L. S. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70726-4 · Cited by 342
Van Poznak, C. H., Temin, S., Yee, G. C., Janjan, N. A., Barlow, W. E., Biermann, J. S., Bosserman, L. D., Geoghegan, C., Hillner, B. E., Theriault, R. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5209 · Cited by 342
Self-citationWildiers, H., Kunkler, I., Biganzoli, L., Fracheboud, J., Vlastos, G., Bernard-Marty, C., Hurria, A., Extermann, M., Girre, V., Brain, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70378-9 · Cited by 338
Eastell, R., Hannon, R. A., Cuzick, J., Dowsett, M., Clack, G., & Adams, J. E. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060508 · Cited by 325
Tumour macrophages as potential targets of bisphosphonates
Rogers, T. L., & Holen, I. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-177 · Cited by 324
Brufsky, A., Harker, W. G., Beck, J. T., Carroll, R., Tan-Chiu, E., Seidler, C., Hohneker, J., Lacerna, L., Petrone, S., & Perez, E. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3744 · Cited by 321
Bisphosphonate-associated adverse events
Papapetrou, P. D. (2009) · Hormones · doi:10.14310/horm.2002.1226 · Cited by 312
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu544 · Cited by 312
Management of the adverse effects associated with intravenous bisphosphonates
Tanvetyanon, T., & Stiff, P. J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj105 · Cited by 301
Bisphosphonate Associated Osteonecrosis of the Jaw
KHAN, A. A., SÁNDOR, G. K. B., DORE, E., MORRISON, A. D., ALSAHLI, M., AMIN, F., PETERS, E., HANLEY, D. A., CHAUDRY, S. R., LENTLE, B., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080759 · Cited by 280
Hadji, P., Aapro, M. S., Body, J.-J., Gnant, M., Brandi, M. L., Reginster, J. Y., Zillikens, M. C., Glüer, C.-C., de Villiers, T., Baber, R., et al. (2017) · Journal of Bone Oncology · doi:10.1016/j.jbo.2017.03.001 · Cited by 277
Management of bone metastases in cancer: A review
Selvaggi, G., & Scagliotti, G. V. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.011 · Cited by 266
Third consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp261 · Cited by 263
Drug-induced Osteoporosis: Mechanisms and Clinical Implications
Mazziotti, G., Canalis, E., & Giustina, A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.02.028 · Cited by 262
Implementing the Exercise Guidelines for Cancer Survivors
Wolin, K. Y., Schwartz, A. L., Matthews, C. E., Courneya, K. S., & Schmitz, K. H. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2012.02.001 · Cited by 255
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens
Conte, P., & Guarneri, V. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-28 · Cited by 241
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Zheng, Y., Zhou, H., Brennan, K., Blair, J. M., Modzelewski, J. R. K., Seibel, M. J., & Dunstan, C. R. (2007) · Bone · doi:10.1016/j.bone.2006.09.016 · Cited by 82
Aromatase inhibitors in post-menopausal endometriosis
Polyzos, N. P., Fatemi, H. M., Zavos, A., Grimbizis, G., Kyrou, D., Velasco, J.-G., Devroey, P., Tarlatzis, B., & Papanikolaou, E. G. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-90 · Cited by 63
Metadata
- Authors
- Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., & Brown, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-11-01
- Volume
- 21
- Issue
- 21
- Pages
- 4042-4057
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107118598
- Cited by
- 970
- References
- 46
- FWCI
- 29.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.